

REMARKS

RECEIVED

APR 15 2000

TELETYPE UNIT 1600/2000

The claims are 1-17.

A terminal disclaimer is required to overcome a double patenting rejection under 35 USC 101 over USP 6,005,001. A terminal disclaimer is attached.

The claims are also rejected under 35 USC 103 as obvious over Richter et al., U.S.P. 5,681,849. The rejection is traversed. The present application is a descendant from the application which issued as U.S.P. 5,681,849. Therefore, the claims cannot be rejected under 35 USC 103 over this patent.

It is requested that the Examiner reconsider the rejection in view of the Terminal Disclaimer and remarks and that the case be passed to issue.

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027

  
Gabriel Lopez  
Attorney for Applicants  
Reg. No. 28,440  
(908) 522-6933

GL:mjl

Date: 3/22/00

Attachment: Terminal Disclaimer + Assignment